'Don't eat me' upstart taps Takeda vet on path to the clinic; Greg Mayes leaves Antios for Canadian psychedelics player
Nenad Grmusa was “really happy” at Takeda, where he’d been for more than a decade in various R&D strategy and finance positions. However, the more he learned about DEM BioPharma, the more intrigued he became by cancer’s unexplored “don’t eat me” signals.
Jonathan Weissman and team launched the aptly-named biotech back in June to deploy macrophages and other myeloid effector cells against tumors by using so-called “don’t eat me” and “eat me” signals, which allow cancer cells to evade the immune system.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters